Celyad
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rue André Dumont 9, Mont-Saint-Guibert, ...Phone Number
+32 10394100Website
www.celyad.comRevenue
<$5 MillionStock Symbol
CYADIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Celyad
Celyad is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, with additional operations in New York. The company specializes in the development of CAR-T cell-based therapies targeting cancer. Celyad's innovative platform focuses on creating treatments for both solid and hematologic tumors through advanced cell engineering techniques. The company develops both autologous and allogeneic CAR-T therapies that are currently undergoing clinical trials for conditions including acute myeloid leukemia and metastatic colorectal cancer. As a publicly traded company, Celyad is listed on multiple exchanges including Euronext Brussels, Euronext Paris, and the Nasdaq Global Market under the ticker symbol CYAD.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celyad your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Celyad has new funding data
Check if Celyad has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Celyad recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Celyad had a recent Job posting/layoffs
Check out if Celyad is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Celyad
Celyad, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Celyad launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Celyad
Find 2 more new buyers
Company Profile Activity
Activity Insights
Celyad is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Celyad is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Celyad.
Celyad financials insights
Gather financial insights about Celyad, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Series B
$8.1M
2015
Stock Offering
$100.1M
2021
Share Placement
$40M
Share Placement
$32.5M
Celyad Tech Stack
A closer look at the technologies used by Celyad
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Event
Events
New Hire
Executive Move
Celyad News & Media
Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad”) is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1st, 2024. Matt Kane is a seasoned executive with over 20 years of experience in entrepreneurial, CEO and board roles. Mr. Kane is a pioneer in genome editing, led the development of the first editing technology to receive clearance for clinical evaluation as an in vivoCelyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a rectified notification of transparency dated September 13, 2023, indicatCelyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated September 5, 2023, indicating that CFCelyad Oncology announces receipt of Nasdaq delisting notice
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celyad
Sign Up For FreeTo access detailed company insights
Celyad is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, with additional operations in New York. The company specializes in the development of CAR-T cell-based therapies targeting cancer. Celyad's innovative platform focuses on creating treatments for both solid and hematologic tumors th... Read More
